tadalafil + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostatic Hyperplasia
Conditions
Prostatic Hyperplasia, Prostate
Trial Timeline
Oct 1, 2004 → Jul 1, 2005
NCT ID
NCT00547625About tadalafil + placebo
tadalafil + placebo is a phase 2 stage product being developed by Eli Lilly for Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00547625. Target conditions include Prostatic Hyperplasia, Prostate.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01865084 | Phase 3 | Terminated |
| NCT01460342 | Phase 3 | Completed |
| NCT01152190 | Phase 3 | Completed |
| NCT01130532 | Approved | Completed |
| NCT01026818 | Approved | Completed |
| NCT00848081 | Phase 3 | Completed |
| NCT00855582 | Phase 3 | Completed |
| NCT00836693 | Phase 3 | Completed |
| NCT00422734 | Phase 3 | Completed |
| NCT00538564 | Phase 2 | Withdrawn |
| NCT00386009 | Phase 2 | Completed |
| NCT00547625 | Phase 2 | Completed |
| NCT00382135 | Approved | Completed |
| NCT00381732 | Phase 3 | Completed |
Competing Products
20 competing products in Prostatic Hyperplasia